Sign In
Buy BIIB
$195.96
+7.13 (+3.78%)
At Close: Jun 03, 2026
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
01:00am, Thursday, 04'th Jun 2026
BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts,
Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses
07:30am, Wednesday, 03'rd Jun 2026
CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that fourteen abstracts highlighting data from its nephrology portfolio, including EMPAVELI® (pegcetacoplan)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
04:54pm, Tuesday, 02'nd Jun 2026
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB). Such investors are advised t
BRUSSELS, Belgium and CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced that The Lancet, a world-leading medical journ
Why Is Biogen (BIIB) Up 3.8% Since Last Earnings Report?
12:32pm, Friday, 29'th May 2026
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock?
Should You Buy, Sell or Hold BIIB Stock After it Rises Almost 12% YTD?
10:55am, Friday, 29'th May 2026
Biogen climbs 11.5% YTD as new drugs, pipeline progress and M&A activity fuel confidence in Biogen???s multiyear turnaround.
Biogen Inc. (BIIB) Investors with Losses are Urged to Contact The Gross Law Firm to Discuss Their Rights
09:00am, Friday, 29'th May 2026
NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Biogen Inc.: Due to the forgoing, The Gross Law Firm is investigating potential securities
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
10:00am, Thursday, 28'th May 2026
NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact D
Italy's antitrust regulator opens probe into US Biogen over alleged dominant position
02:27am, Wednesday, 27'th May 2026
Italy's antitrust authority said on Wednesday it had opened an investigation into drug maker Biogen Italia and its parent Biogen over alleged abuse of dominant position.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
04:50pm, Tuesday, 26'th May 2026
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB). Such investors are advised to
Leqembi Isn't Enough To Save Biogen Momentum (Rating Downgrade)
08:11am, Tuesday, 26'th May 2026
Leqembi Isn't Enough To Save Biogen Momentum (Rating Downgrade)
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
01:15pm, Friday, 22'nd May 2026
DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt development in idiopathic cases.
Biogen Inc. (BIIB) Securities Fraud Investigation - Levi & Korsinsky
09:00am, Friday, 22'nd May 2026
Biogen shares dropped approximately 6.4% in a single session after Phase 2 CELIA trial data for diranersen missed its primary endpoint -- wiping out billions in market value. NEW YORK, May 22, 2026 /P
Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish
07:50am, Friday, 22'nd May 2026
U.S. Food & Drug Administration (FDA) events crystallize the risk/reward thesis for many biotechnology stocks, and Biogen Inc.'s NASDAQ: BIIB latest Alzheimer's update shows why that trade can turn q
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
06:40pm, Thursday, 21'st May 2026
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact Dan
